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Summary Immunoscintigraphy with radiolabelled anti-carcinoembryonic antigen monoclonal antibody was
performed on 21 patients with active small-cell lung cancer. Patients received either In-lI 1-labelled Mab F6
F(ab')2 fragments or Tc-99m-labelled BW 431/26 intact antibody.
Tumour was imaged in 13 patients (62%). Of 38 known sites of disease, 18 sites were positively detected.
Serum CEA levels were known in 19 patients and were abnormally elevated in three (tumour being detected in
all three patients). Eight of 15 patients with normal serum CEA had positive imaging. Using the In-111-
labelled antibody seven out of ten patients (nine out of 18 sites) gave positive scans; with the Tc-99m-labelled
antibody these were obtained in nine out of 18 patients (nine out of 20 sites).
Considerable interest has developed in the identification of
antigens expressed by small-cell lung cancer (SCLC) cells,
and with the production of monoclonal antibodies (Mabs)
which react with them. Many such Mabs are emerging. A
recent serological study of 87 candidate monoclonal
antibodies has resulted in the assignment of 33 Mabs to
seven clusters associated with SCLC (Beverley et al., 1991). If
highly specific Mabs can be produced, in addition to diagnos-
tic imaging, the possibility of targetted therapy using Mabs
conjugated with toxins or therapeutic radioisotopes will arise.
Before such treatment can be considered, a Mab must be
shown to selectively localise within tumours in vivo. If it does,
then clinically detectable tumour masses should be
identifiable by immunoscintigraphy. However there have
been few published studies on the immunoscintigraphy of
lung cancer (Perkins et al., 1986; Bourguet et al., 1990). If
imaging is to be undertaken there is still debate concerning
which radionuclide will prove to be the most useful
radiolabel and which form of antibody or fragments will
produce the most contrast between tumour and normal tis-
sues.
Technetium-99m (Tc-99m) and Indium- 111 (In-111) have
been widely used in immunoscintigraphy. The lower gamma
ray energy emitted from Tc-99m (physical half-life 6 h) gives
better resolution with most imaging equipment, but the
longer physical half-life of In-l (2-8 days) permits imaging
2-3 days following administration, when the tumour-to-
tissue concentration of the Mab may be more favourable.
Carcinoembryonic antigen (CEA) is an oncofoetal protein
which has been reported to be expressed by up to 70% of
SCLC cell lines (Goslin et al., 1981). Anti-CEA Mabs are
widely available, so although they are less specific for SCLC
than other antibodies, they were a convenient material to use
in the preliminary investigation of the immunoscintigraphy of
SCLC.
The present study investigates the performance of two
anti-CEA monoclonal antibodies labelled with Tc-99m or
In-l11 in the immunoscintigraphy of SCLC.
Methods
Twenty-one patients were imaged; nine had newly diagnosed
SCLC and 12 had relapsed after initially responding to con-
ventional therapy. All had histologically proven disease and
none had received active treatment in the month prior to
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imaging. Sites of involvement were determined by clinical
examination, chest radiograph and supplementary radio-
logical investigation as appropriate. The two anti-CEA Mabs
used were F(ab')2 fragments of antibody F6 (Oris Industrie,
France) radiolabelled with 80 MBq In-l 1(10 patients), and
intact BW431/26 (Behringwerke, Germany) radiolabelled
with 1000 MBq Tc-99m (11 patients).
Following slow intravenous injection the patients were
imaged using a large field of view gamma camera (IGE
400ac) fitted with an appropriate energy collimator. Anterior
and posterior images of the thorax and abdomen were
recorded containing approximately 600 k counts and stored
by computer in a 128 x 128 matrix. The imaging parameters
are shown in Table I. Within 20 minutes of administration a
'blood pool' image was taken. This was then compared with
a second scan recorded after allowing time for the Mab to
localise within the tumour: 24 h in the case of Tc-99m-
labelled Mab and 72 h in the case of In-l 11-labelled Mab.
Three of the authors assessed the images, and scored the
degree of tumour localisation in each patient using a subjec-
tive arbitrary scale from 0 to + + + +.
The original formalin fixed, paraffin-embedded diagnostic
biopsies were available on 18 patients; the remaining three
were diagnosed on cytology. These biopsies were examined
immunohistochemically using a standard immunoperoxidase
technique with four anti-CEA monoclonal antibodies: the
two scanning antibodies (F6, BW431/26), CEA and CEA/
NCA (both CRC Laboratories, Nottingham).
Results
The results of the investigations are shown in Table II
together with clinical data.
No adverse effects were observed following administration
of either Mab. The images obtained from patients
administered with both radiolabelled antibodies showed
uptake throughout the reticulo-endothelial system with a
Table I Imaging parameters
Tc-99m-BW431/26 In-ll-Mab F6
Molecular form IgGI F(ab')2
Protein dose 2 mg 1 mg
Radioactive dose 1000 MBq 80 MBq
Collimator Low energy Medium energy
Photopeaks 141 keV 173, 247 keV
Imaging times 20 min, 24 h 20 min, 72 h
Approx count rates 2000 cps 5000 cps
(anterior thorax)
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Table II
Patient
I 1
2 1
3 1
4 1
5 J
Newl
recurrent
R
N
R
R
R
FH
RH
MB
FW
JK
6 EH N
7 MN R
8 JA R
9 MS N
10 AM N
11 PO N
12 NH R
13
14
15
16
17
WG N
SM R
DE N
GP
BK
N
R
18 NW R
19 FP R
Serum CEA
<lOmcgl-'
Neg 2.1
Neg 7.6
Neg < I
Neg <1
Neg <1.5
Neg 2.2
Neg 7.3
Neg <1
Pos 42.4
Neg 1.9
Pos 35.8
Neg 6.5
Neg 1.9
Neg 9.5
Neg 4.5
Neg <1
Neg 4.5
Pos 19.6
20 DL R
21 AMN N
Scan
In
In
In
In
In
0
0
0
In ++
In
In
Tc
Tc
Tc
TC
Tc
In
In
Scan sites
Hemithorax;
liver
R upper lobe
R middle zone
++++ R hilum
+ + + Mediastinum;
L lung
+ Mediastinum
0
0
Tc +
Tc 0
Tc
Tc
Tc
0
L hilum;
neck nodes
Liver
Neck node
R lower lobe
L hilum;
bone
R upper lobe;
liver
R upper zone
Tc 0
Disease sites
Hemithorax, liver;
coeliac nodes.
R upper lobe; liver
Mediastinum
Adrenal; mediastinum
Adrenal; liver;
neck nodes
R middle zone;
bone
R hilum
Mediastinum;
L lung; bone
Mediastinum;
neck node
L hilum;
neck nodes
Pleural effusion
Pleural effusion;
liver
R lung
Neck node
R lower lobe;
skin
L hilum;
bone
Hemithorax;
neck node
Hemithorax
R upper lobe;
liver
R upper zone;
neck node
Mediastinum
high level of activity in the liver. This pattern of uptake was
evident from the early blood pool images and persisted in the
later views. The early blood pool views of the thorax demon-
strated activity in the heart which was reduced in the later
views. Positive uptake was observed at tumour sites in all
three patients known to have elevated levels of serum CEA,
and also in nine who showed no abnormality in serum
marker level. One other patient whose serum CEA was unk-
nown also had a positive scan, making a total of 13 patients
with positive imaging (62%). In ten of these, the degree of
tumour localisation was assessed as strongly positive (+ + +
or + + + +). Within the group of 21 patients, 38 separate
sites of bulk diseases were known, and 18 of these were
positively imaged (47%). Four examples ofpositive scans are
illustrated (Figures 1-4).
Of ten patients studied with In-l 1 labelled antibody,
seven were positive (9/18 sites) as were 6/11 receiving Tc-99m
(9/20 sites). A total of five patients had liver metastases.
Liver metastases were detected in 2/2 patients studied with
Tc-99m-Mab whereas use of the In-lI l-F(ab')2 antibody
failed to detect liver metastases in three patients.
Immunohistochemical examination of the 18 histological
specimens using the panel of four anti-CEA Mabs gave
positive staining in five; four ofthese were positive to all four
Mabs and the other reacted to the two Mabs not used for
scanning, but not the the scanning Mabs. Of the five positive
on immunohistochemistry, three had given positive scans;
conversely there were eight assessed histochemically on
whom positive scans were obtained but who showed no
immunoreactivity. Thus, no correlation was seen between
uptake as shown by immunoscintigraphy and that of
immunohistochemistry.
Discussion
In SCLC, only patients achieving complete response to con-
ventional treatment have stood any chance of cure, but even
in this group resistant micrometastases lead to relapse and
ultimate death for the great majority. Targetted therapy with
Mabs reacting with SCLC tumour antigens might be a way
of eradicating such micrometastases, and thereby increasing
cure rates. Before such treatments can be considered, uptake
of Mab by the tumour must be demonstrated. Immunoscinti-
graphy provides a useful means of showing such uptake in
vivo. There are, however, little published data on the localisa-
tion of SCLC by immunoscintigraphy. We have previously
demonstrated successful imaging ofvarious histological types
of lung cancer (SCLC included) using an anti-72000 dalton
glyoprotein associated antibody (Perkins et al., 1986). Our
present study has demonstrated that detectable uptake by
SCLC occurs in vivo in more than half the patients studied
using anti-CEA Mabs which are not specific to SCLC.
The relationship of serum CEA with outcome of the scan
is surprising. All three patients with elevated serum CEA had
positive imaging, but it is interesting to note that eight of 15
patients with normal serum CEA still had positive scans.
Although Goslin et al. (1986) reported 70% of patients with
SCLC to have elevated serum CEA, we saw only three
patients with raised levels out of 18 assessable (17%). It is
pertinent to note that Goslin et al. used a serum assay with
an upper limit of normal for serum CEA of 2.5mcg.1-'
whereas we used an assay with a higher value of 10mcg.lh'.
Six patients had serum CEA levels between 2.5-10mcg.l1',
and of these, four had positive imaging. It is of course
possible that false-positive uptake visualised on imaging is
due in part to non-specific localisation in inflammatory tis-
sue. This consideration would apply to all studies using
radiolabelled antibodies and could only be clarified by using
a non-specific immunoglobulin of the same isotype used for
imaging. It was not possible to perform this study in the
present series of patients.
It is important to emphasise that the anti-CEA antibody
preparations used in the present study were different, with
intact BW 431/26 antibody radiolabelled with Tc-99m and
F6(ab')2 fragments radiolabelled with In-i 11. Factors such as
antibody fragmentation, affinity constant and choice of
radiolabel will all affect the performance of the preparations.IMMUNOSCINTIGRAPHY OF SCLC 1393
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Figure 1 Patient number 1: anterior image of thorax 72 h fol-
lowing injection of In-l11-F6 F(ab')2 anti-CEA antibody, show-
ing increased uptake in the lower two-thirds of the left hemi-
thorax a, corresponding with the abnormality seen on the chest
x-ray b.
This study therefore does not attempt to make a direct
comparison of the radiolabels or Mabs, but has compared
the imaging results obtained from the final radiopharma-
ceutical conjugates, which are currently under evaluation for
commercial production. Poor correlation was observed
between the scanning and immunohistochemical results with
scanning producing more positive results. However, the two
methods used are very different; monoclonal antibodies react
with very specific epitopes which may be affected by formalin
fixation, tissue processing and paraffin embedding. Immuno-
histochemical staining was not strong in any of the positive
b
Figure 2 Patient number 7: anterior image of thorax 72 h fol-
lowing injection of In-ill-F6 F(ab')2 anti-CEA antibody, show-
ing increased uptake in the right lung a, corresponding to the
mass seen on chest-x-ray b.
cases, suggesting the possibility of low antigen concentrations
or inadequate sensitivity of the assay.
Both In-Ill and Tc-99m labelled antibody preparations
proved to be useful with no marked difference in perfor-
mance. The shorter half life of Tc-99m however, required
imaging at 24 h following injection of the Mab, rather than
48-72 h for In-I1, thus reducing the amount of time that
tumour is exposed to Mab. This seems to offset any disad-
vantage due to the inferior resolution of the higher energy of
gamma rays emitted by In-Ill (173, 247 keV compared to
141 keV). A higher detectable count rate per unit dose was
obtained with In-11l (5,000 cps vs 2,000 cps), leading us to
favour this radionuclide for future studies. However, it is
interesting to note the relative abilities of the antibodies for
the detection of liver metastases, the Tc-labelled F6(ab')2
a
R
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Figure 3 Patient number 14: anterior image of thorax 72 h
following injection of In-l11-F6 (F(ab )2 anti-CEA antibody,
showing increased uptake in a clinically-enlarged right suprac
lavicular node. (There is no increased uptake in the chest, nor
any radiological evidence of recurrence here in this patient in
whom the node was the only evidence of relapse after previous
response to chemotherapy and thoracic radiotherapy).
performing better in this small series.
This study has demonstrated that it is possible for anti-
CEA Mab to localise within deposits of SCLC in vivo
sufficiently to permit external imaging using a gamma
camera. With the identification of more specific SCLC
antigens, the development of new Mabs will hopefully lead to
the possibility of Mab-targetted therapy. Demonstration of
tumour uptake by immunoscintigraphy will be an essential
step in the assessment of such Mabs prior to their therapeutic
use.
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